Expanding targeted therapy to NRAS-mutated melanoma

The Lancet Oncology

Volumn 14, Issue 3, 2013, Pages 186-188

  Gibney, Geoffrey T ^a   Weber, Jeffrey S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRY 438162; B RAF KINASE; CREATINE KINASE; DABRAFENIB; IPILIMUMAB; RECOMBINANT INTERLEUKIN 2; SELUMETINIB; TRAMETINIB; VEMURAFENIB;

BRAF GENE; BRAIN METASTASIS; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CREATINE KINASE BLOOD LEVEL; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; GENE MUTATION; HUMAN; LETTER; LONG TERM SURVIVAL; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; ONCOGENE N RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SIDE EFFECT; SURVIVAL TIME; WILD TYPE;

BENZIMIDAZOLES; FEMALE; HUMANS; MALE; MELANOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84875239306     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70054-8     Document Type: Letter

References (12)

1. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, published online Feb 13, 2013. http://dx.doi.org/10.1016/S1470-2045(13)70024-X.
2. Dry JR, Pavey S, Pratilas CA, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010, 70:2264-2273.
3. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:782-789.
4. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012, 18:555-567.
5. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
6. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
7. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012, 18:2039-2047.
8. Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012, 35:66-72.
9. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
10. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
11. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
12. Kwong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012, 18:1503-1510.